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ABSTRACT Expedited pathways to antimicrobial agent approval by the U.S. Food
and Drug Administration (FDA) have led to increased delays between drug approval
and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices.
Antimicrobial disks for use with disk diffusion testing are among the ﬁrst AST de-
vices available to clinical laboratories. However, many laboratories are reluctant to
implement disk diffusion testing for a variety of reasons, including dwindling proﬁ-
ciency with this method, interruptions of the laboratory workﬂow, uncertainty sur-
rounding the quality and reliability of disk diffusion tests, and a perceived need to
report MIC values to clinicians. This minireview provides a report from the Clinical
and Laboratory Standards Institute Methods Development and Standardization
Working Group on the current standards and clinical utility of disk diffusion testing.
KEYWORDS antimicrobial susceptibility testing, CLSI, disk diffusion, EUCAST, FDA
All antimicrobial susceptibility testing (AST) devices marketed in the United Statesare regulated by the Food and Drug Administration (FDA) Center for Devices and
Radiological Health (CDRH). In contrast, antimicrobials are regulated by a separate
branch of the FDA, the Center for Drug Evaluation and Research (CDER). AST devices
used by clinical laboratories can be broadly categorized into automated and manual
methods. Automated AST devices available in the United States include the Vitek II
(bioMérieux, Durham, NC), MicroScan (Beckman-Coulter, West Sacramento, CA), Phoe-
nix (Becton, Dickinson and Company, Sparks, MD), Sensititre (ThermoFisher Scientiﬁc,
Lenexa, KS), and PhenoTest (Accelerate Diagnostics, Tucson, AZ) systems. Manual AST
devices include disks, gradient diffusion strips (i.e., Etest [bioMérieux] and MIC test
strips [MTS] [Lioﬁlchem, Italy]), and lyophilized MIC panels (Sensititre manual panels).
Automated AST devices involve sophisticated instrumentation and software, which
provide both improved testing standardization (e.g., objective reading of endpoints
and closed-system incubation) and generally less hands-on technologist time than is
required by manual methods. When performed according to the manufacturer’s in-
structions, some automated AST devices yield results more rapidly than do manual
methods (1–3). Additionally, “expert rule” software is typically provided along with
automated AST devices, which helps mitigate the risk of the laboratory reporting
erroneous susceptibility results and helps ensure compliance with regulatory guidelines
Accepted manuscript posted online 9 May
2018
Citation Humphries RM, Kircher S, Ferrell A,
Krause KM, Malherbe R, Hsiung A, Burnham
C-AD. 2018. The continued value of disk
diffusion for assessing antimicrobial
susceptibility in clinical laboratories: report
from the Clinical and Laboratory Standards
Institute Methods Development and
Standardization Working Group. J Clin
Microbiol 56:e00437-18. https://doi.org/10
.1128/JCM.00437-18.
Editor Colleen Suzanne Kraft, Emory University
Copyright © 2018 American Society for
Microbiology. All Rights Reserved.














and standards, such as those published by the Clinical and Laboratory Standards
Institute (CLSI) (4). For these reasons, most U.S. clinical laboratories have converted to
automated AST devices for the bulk of, if not all, their AST needs. By way of example,
a 2016 survey of clinical laboratories in California reported that 84 (94.4%) of 89
surveyed laboratories performed AST exclusively with one of the automated systems
listed above (5). With this reliance on automated methods, laboratory competency and
comfort with manual AST devices have dwindled. In recent years, a dilemma has
emerged with this scenario, as the only AST devices available for recently approved
antimicrobial drugs are manual tests (Table 1).
The process for developing an AST device for a new antimicrobial drug is complex,
expensive, and time-consuming. Development of automated AST devices to accom-
modate new drugs is generally a lengthier process than development of manual tests,
because not only the test itself but also the instrumentation and software must be
updated. As a result, new drugs are often not available on automated AST devices until
many years after the new drug application (NDA) for an antimicrobial is approved by
the CDER (Table 1) (5, 6). In contrast, manual AST devices are typically available prior to
or soon after NDA approval. These manual tests may be distributed as research use only
(RUO) products pending the availability of in vitro diagnostic (IVD) labeled devices,
which are usually cleared by the CDRH within 6 months after NDA approval. New
pathways that facilitate antimicrobial drug approvals, such as expedited development
programs, shortened regulatory review, and 505(b) NDA approvals (2), have brought
antimicrobial agents to market faster than ever before. While this is wonderful progress,
the challenge for clinical laboratories is that these expedited pathways do not have any
means to address the gap between drug approval and AST device clearance, even for
manual tests, in part due to the number of new antimicrobials entering the market-
place. Since 2010, eight antibacterial agents that require AST have been approved by
the FDA (Table 1). This demand for AST device development is compounded by
ongoing breakpoint revisions, which also must be addressed by AST device manufac-
turers. For instance, the CLSI has revised 28 breakpoints in the M100 standard since
2010 (4). Addressing these updates may require new development or reformulation of
the antimicrobials in question, new clinical trials, and software updates by AST device
manufacturers. In combination, these advancements have put tremendous resource
and ﬁnancial strains on AST device manufacturers, which may further extend the time
to automated AST device availability. These dilemmas have not gone unnoticed by the
FDA. In September 2016, the FDA published a draft guidance (7) and held a public
workshop that discussed pathways for pharmaceutical companies and device manu-
facturers to coordinate efforts to achieve device clearance coinciding with (or occurring
soon after) drug approval. Recent AST device clearances demonstrate success with this
approach. Three manual devices for testing delaﬂoxacin, which obtained FDA approval
on 19 June 2017, were cleared by the CDRH within 44 days after approval of the drug
















Delaﬂoxacin 6/2017 2 2 2 NA
Meropenem-vaborbactam 8/2017 2 4 4 6
Ceftazidime-avibactam 2/2015 8 7 10 25
Ceftolozane-tazobactam 12/2014 11 19 8 36
Dalbavancin 5/2014 ND 25 14 NA
Oritavancin 8/2014 ND NA 7 NA
Tedizolid 6/2014 NA 36 15 NA
Ceftaroline 5/2010 7 29 14 34
aTimes were rounded to the nearest month. NA, not available; ND, no disk test is possible due to drug characteristics.
bThe average time to clearance, from the time the 510(k) data package is submitted to the FDA, is 42 days for the disk manufacturers that participated in the
sponsor’s clinical trials.
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by the CDER (data publicly available by searching the FDA website). Similarly,
meropenem-vaborbactam AST devices were cleared by the CDRH within 112 days after
NDA approval of this drug on 29 August 2017; disks were cleared 35 days after NDA
approval. Such expedient development and clearance of AST devices are far more
feasible for manual AST devices than for automated AST devices (Table 1), and it is likely
that manual tests will remain the only AST devices available for new drugs in the near
future. Furthermore, even when an automated AST device is cleared, it may be several
years before the manufacturer markets the test, largely due to software update
requirements for the instruments used by laboratories.
Many laboratories are unfortunately hesitant to introduce manual AST devices into
their routine clinical practice. The reasons for this reluctance are complex but may
include the labor associated with performing manual tests, dwindling staff proﬁcient in
performing manual tests, and purchasing contract restrictions (e.g., if a disk is available
only from one manufacturer and the laboratory has a purchasing contract with a
different manufacturer of disks). Laboratories have also expressed concern regarding
disk tests speciﬁcally, due to reported issues with disk quality (http://www.eucast.org/
ast_of_bacteria/warnings/#c13111), performance issues (8–10), or the perception that
MIC values are needed to guide patient therapy. Nonetheless, laboratories must
develop a strategy for testing new antimicrobial drugs. Such drugs are often the only
drugs available to treat multidrug-resistant Gram-negative bacteria, and delays in
implementing testing for these antimicrobials limit the ability of physicians to treat
life-threatening infections (11, 12).
In recognition of the challenges faced by laboratories in performing timely AST of
new antimicrobial drugs, the CLSI AST Subcommittee has formed an ad hoc working
group (ahWG) to address the challenges surrounding the coordinated development of
new antimicrobial drugs and AST devices and testing of such drugs by clinical labora-
tories. One primary objective of the ahWG is to provide context regarding the current
standards for disk diffusion testing, given that this methodology is one of the few AST
methods available for new drugs. This minireview was developed by the ahWG to
illuminate the process of antimicrobial disk development, to describe how disk break-
points are established, to review the established controls for disk quality, and to
comment on the clinical value of disk diffusion results.
DEVELOPMENT PROCESS FOR DISKS
Determination of disk mass. Prior to an antimicrobial drug entering human clinical
trials, the sponsoring pharmaceutical company (sponsor) collaborates with device
manufacturers to develop disks for testing the activity of the drug against individual
clinical isolates. The sponsor generally works with one or more reference laboratories
that maintain large collections of recent clinical bacterial isolates. The reference labo-
ratory determines the optimal disk mass (the concentration of antibiotic within the
disk) by evaluating disk diffusion and reference broth microdilution (BMD) tests in
parallel against an organism set, ideally using the same inoculum to minimize variabil-
ity. The studies typically include 100 isolates, representing the genera and species
that are associated with the infections of interest for the antimicrobial. It is critical that
the study include isolates with MICs that span the full range of the MIC distribution, to
ensure that the test can discriminate susceptible from tentatively resistant isolates, thus
minimizing very major errors (VMEs) (i.e., isolates resistant by BMD testing but suscep-
tible by disk diffusion testing) and also major errors (MEs) (i.e., isolates susceptible by
BMD testing but resistant by disk diffusion testing). The disk mass for antibiotic
compounds in the same drug class is taken into consideration as a starting point for this
process. However, the performance characteristics of multiple disk mass options that
extend below the expected mass are also studied, with the goal of deﬁning the minimal
disk mass that meets deﬁned performance criteria. This approach yields smaller zone
sizes that are easier to measure, may be less prone to error, and allow testing of
multiple disks on the same plate. At this early stage of development, the reference
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laboratory often manufactures the disks in-house, by manually aliquoting the antibiotic
onto blank, sterile, paper disks.
The data obtained during these studies are analyzed using scattergrams of zone size
versus MIC, as described in CLSI document M23, section 2.3 (13). Historically, if no
signiﬁcant difference in performance was noted between disk masses, then the mass
that most closely matched the one used for other antimicrobial drugs of the same class
was selected. However, there is now an effort to choose the lower disk mass, which
facilitates global harmonization. If signiﬁcant performance differences between disk
masses are seen, then the mass that most closely meets the susceptible criterion of 15
to 35 mm, as also described in CLSI document M23, section 2.3 (13), is chosen, to
maximize the number of disks that can be tested on a single plate. To date, disk masses
deﬁned by CLSI and European Committee on Antimicrobial Susceptibility Testing
(EUCAST) standards have not always been harmonized. In 2017, however, a joint
working group on disk testing was formed between CLSI and EUCAST, which aims to
facilitate standardization of disk masses between the two organizations. To aid in this
process and to ensure an expedient review of disk quality control (QC) ranges, drug
sponsors are encouraged to engage the joint working group early in the development
process. Early harmonization can simplify the disk development process, ensure that
disk zone data collected from antimicrobial drug clinical trials use a disk that satisﬁes
the regulatory approval requirements of both the FDA and the European Medicines
Agency (EMA), and allow comparison of disk test results across geographically distinct
studies that might otherwise have used different disks.
Production-scale manufacturing. Once the optimal disk mass has been deter-
mined, the sponsor initiates development with commercial disk manufacturers, as
larger scale lots are necessary to establish QC ranges, according to document M23 (13).
To initiate the development process after all legal agreements have been completed,
the sponsor provides the antibiotic powder, a certiﬁcate of analysis, and the material
data sheet. In the early stages, the disk manufacturer prepares small-scale, benchtop
preparations to conﬁrm the solubility and potency. Batches of disks are prepared from
ﬁlter paper cardstock of the required composition and thickness for standard disk
diffusion testing. Standard disks have the ability to absorb 2.5 to 3.0 times their weight
of distilled water. The cardstock must not exhibit inhibitory activity or contain residual
material (e.g., oil and debris) that would affect the activity or pH of the antibiotic
solution.
Using the sponsor’s recommendations for mass, solvent system, and other deﬁned
conditions (e.g., preheating the ﬁlter paper cardstock), the cards are saturated with the
antibiotic solution, excess moisture is removed, and the cards are oven dried, following
each manufacturer’s process. For this initial batch, the cards may be manually punched
to produce the desired number of disks. The high-volume manufacturing process is
mimicked as closely as possible. When the optimal preparation conditions have been
determined through disk diffusion performance and/or high-performance liquid chro-
matography (HPLC) assessments of disk antimicrobial contents, a standardized manu-
facturing protocol (SMP) is drafted and prototype disks are manufactured. Manufac-
turing facilities that produce disks follow a quality management system that complies
with ISO standards, i.e., ISO 9001, ISO 13485, and/or ISO 14001 (https://www.iso.org/
standards.html).
Generally, a small pilot lot of disks are packaged into cartridges following the SMP.
The disks are then tested to conﬁrm accurate zone diameters and reproducibility.
Analytical tests, such as an HPLC assay and/or a bioassay to verify the drug concen-
tration, may also be performed, based on the sponsor’s recommendations. Any failures
from this testing require reevaluation of the production process, to determine whether
and where changes are needed.
After a pilot lot is produced with acceptable performance, subsequent lots are
produced by stacking cards and feeding them through an automated process to be
punched into single cartridges with a desiccant, blister sealed, and labeled with
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information speciﬁcally deﬁned by the sponsor. The disk manufacturer continues to
monitor the performance of multiple lots to establish stability and expiration dating;
this is accomplished through both accelerated and real-time stability testing. Acceler-
ated testing may include storage of the disks at 25°C and 35°C, with testing at various
intervals. Depending on the antibiotic, real-time stability testing is conducted for a
period of up to 27 months when disks are stored at the recommended storage
temperature (e.g., 2°C to 8°C). The disks may be provided back to the sponsor for formal
QC testing after accelerated stability testing, if performance is acceptable.
Establishing QC ranges. The sponsor initiates formal QC studies by working with a
reference laboratory to test a large number of organisms and predeﬁned QC isolates.
In these studies, at least one disk lot from two manufacturers or two disk lots from the
same manufacturer (if only one disk manufacturer collaborated with the sponsor to
develop disks) and one lot of Mueller-Hinton agar from three different manufacturers
are used (13). The data are then compiled, reviewed, and proposed to the CLSI AST
subcommittee for approval. The subcommittee determines whether the data are
sufﬁcient for the establishment of QC zone sizes, and it may recommend further testing.
Additional QC isolates that are speciﬁc to the new drug (e.g., an organism that can
properly measure both components of a -lactam--lactamase inhibitor combination)
may be added. Once the proposed QC zones are approved, they are published in the
QC table of the M100 document, which is updated every January.
Establishing disk breakpoints. Following the establishment of QC ranges, the drug
sponsor progresses to testing contemporary clinical isolates, such as those collected
during prospective surveillance studies and those isolated during the sponsor’s phase
III clinical trials. These clinical studies involve collecting specimens from hundreds of
patients, isolating the infecting bacterium, and testing the susceptibility of each
recovered isolate with the disk and reference BMD methods, which are performed in
parallel, using the same inoculum. Multiple specimens are collected from each patient
enrolled in the trial, i.e., one prior to administration of the antimicrobial drug (baseline)
and additional specimens as clinically indicated if the infection persists. For some
indications, such as urinary tract infections or complicated skin and skin structure
infections, additional specimens may be taken daily, using noninvasive procedures,
after the antimicrobial therapy commences. QC testing is performed on each day of
clinical isolate testing. As a result, every isolate has a measured disk zone and MIC value,
as well as QC results from that day of testing. These tests are repeated if QC values are
out of range. QC data are collected and analyzed at the end of a clinical study for
inclusion in the NDA submitted to the FDA. Disk zone diameter interpretive criteria
(breakpoints) for each target organism are determined based on correlations with the
MIC data collected during the phase III clinical studies, with the goal of minimizing
categorical errors. The drug sponsor also presents these data to CLSI and EUCAST, and
the breakpoints are added to the appropriate tables in CLSI document M100 and in the
EUCAST breakpoint documents.
The sponsor prepares the ﬁnal NDA submission and also provides the speciﬁcations
to disk manufacturers, including updated zone breakpoint criteria and the indicated
organism list. The drug sponsor maintains communication with disk manufacturers
throughout the drug approval process, to ensure that the disk labeling for the disk
brand that was evaluated during the drug approval process can be submitted for FDA
clearance as soon as possible following NDA approval. At the present time, this involves
a labeling review only for the disk brand that was evaluated as part of the drug
approval process and met the acceptance criteria. However, to demonstrate that all
disks provide equivalent performance, new testing requirements have recently been
requested by the FDA for clearance of a disk brand not evaluated during the drug
approval process. At the time of this writing, discussions between the FDA, disk
manufacturers, and drug sponsors to deﬁne these testing requirements are under way.
If this additional testing is required, it will extend the time from NDA approval to the
availability of disks from manufacturers not evaluated during the drug approval pro-
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cess; this could limit the ability of laboratories to test new drugs if the laboratories do
not have contracts with the initial manufacturer included in the drug approval process.
This concern is particularly pressing for the 12 new antimicrobial drugs that have
recently been approved by the FDA, are awaiting FDA approval, or are midway through
the development process.
Ongoing quality assessments. Once the disks are available for sale, the disk
manufacturer performs stringent QC testing on each lot of disks produced. For each
antimicrobial drug, QC testing minimally consists of the CLSI-recommended strains. If
the manufacturer also makes media, then all recommended media are included in the
testing. Additional QC strains and/or analytical tests may be used as well. Once the new
lot passes QC testing, the lot of disks can be released for sale. A certiﬁcate of analysis,
which typically includes the assay potency and range, accompanies each lot and is
available on the disk manufacturer’s website. Table 2 summarizes these steps in disk
development. While not required, some degree of postmarketing performance assess-
ment (i.e., MIC versus disk diffusion testing) is performed with selected disks and drugs.
In general, however, stability data that support the shelf life and QC performance of
each disk prior to release are used to ensure the quality of the product. In addition, the
manufacturer monitors performance via the complaint feedback system. All complaints
are investigated, retained samples of the speciﬁc batch or lot are tested with QC and
clinical strains, and the root causes of any observed errors are determined, when
possible.
TABLE 2 High-level overview of disk development
Step Description
Drug sponsor engages reference laboratory Small number of disks are made by hand
Optimal disk mass is determined
MIC correlates are evaluated
Drug sponsor works with disk manufacturers CDA and development agreements are signed
Powder, with certiﬁcate of analysis and material data sheet, is provided to
manufacturer by sponsor
Small-scale, benchtop preparations of disks are made and used by
manufacturer to conﬁrm solubility and potency
Optimal preparation conditions are determined through biological and
chemical checks by manufacturer
Standardized manufacturing protocol is drafted
Disk manufacturer produces RUO disk lots Manufacturer follows standardized manufacturing protocol to produce small
prototype batch of disks in cartridges
Prototype disks are tested to conﬁrm accurate zone diameters and
reproducibility
Subsequent RUO lots are provided to sponsor by manufacturer, with
labeling as deﬁned by sponsor
Disk performance continues to be monitored by manufacturer through
stability studies
RUO lots are provided to reference laboratory QC studies are performed following CLSI M23 guidelines
QC data are presented by sponsor to CLSI AST subcommittee for approval
QC range is established
Reference laboratory tests RUO disks against isolates collected during clinical
trials and establishes disk-MIC correlates (i.e., disk breakpoints)
Drug sponsor submits NDA to FDA Data from clinical trials, including disk breakpoints, are compiled for NDA by
sponsor and presented to CDER
Data may also be presented by sponsor to CLSI and EUCAST for review and
inclusion in breakpoint tables
Drug sponsor provides ﬁnal speciﬁcations included in approved NDA to all
interested disk manufacturers
Post-NDA approval Disk manufacturers involved in drug sponsor’s clinical trial may submit disk
labeling to CDRH
Testing requirements for disk manufacturers not involved in drug sponsor’s
clinical trials have yet to be determined
After 510(k) clearance, disks can be stocked for sale
Disk manufacturer continues to perform QC testing for each new lot of disks
aCDA, conﬁdential disclosure agreement.
Minireview Journal of Clinical Microbiology










CLINICAL VALUE OF DISK DIFFUSION TESTING
One of the primary arguments against the use of disks is that disk diffusion testing
does not generate MIC values. MIC values are being used with increasing frequency to
optimize antibiotic therapy, through individualized pharmacokinetic/pharmacody-
namic models designed to improve drug exposure for difﬁcult-to-treat infections.
However, these models assume that the MIC is an absolute value. As recently reviewed
by Mouton and colleagues, the use of laboratory-measured MICs to determine individ-
ualized pharmacokinetic/pharmacodynamic targets is not advisable (14). The accuracy
of MIC measurements with the reference BMDmethod is within 1 doubling dilution (i.e.,
MIC of 2 g/ml is precise within 1 to 4 g/ml). An excellent example of this is the
accepted vancomycin QC range for Staphylococcus aureus ATCC 25923, which is 0.5 to
2.0 g/ml. This range is due to small uncontrolled variables in the test, such as minor
differences in lots and brands of media and differences in inoculum preparation,
incubation time, and incubation temperature (15). Medium and drug lot differences
have speciﬁcally been shown to result in differences in vancomycin MICs, as have test
methods. S. aureus vancomycin MICs differ consistently between Etest and BMD
methods (16), and BMD MICs vary according to the source of the drug powder and
Mueller-Hinton agar (17). Such variance may also be attributable to biological variability
among the strains, including factors outside resistance mechanisms, such as division
rates and metabolic status (14, 15). There are some advocates for the idea that a
vancomycin MIC value of 2 g/ml for S. aureus may be an indication not to use
vancomycin for treatment, even though the isolate is susceptible (18–20). This idea is
problematic, given that even a QC strain demonstrating good reproducibility may yield
test results of 0.5 g/ml or 2 g/ml. In addition, if the speciﬁc MIC value is used for
dosing calculations, then different results would be obtained if a value of 0.5 g/ml
versus 2 g/ml was used for the calculations (21). For these reasons, pharmacodynamic
targets published in the literature are established by replicate testing of strains in a
single laboratory, using reference methods, and not by a single MIC measurement, as
performed in clinical laboratories for routine patient testing. Overinterpretation of the
precision of a speciﬁc MIC value may have unintended consequences for therapeutic
decision-making and/or may contribute to overestimation of “MIC creep” in longitudi-
nal studies (22–25). It should be noted that disk diffusion testing is also subject to
variability. As an example, the CLSI M23 document accepts QC ranges of 4 dilutions
for MICs and 12 mm for disk diffusion tests (13). In practice, the precision of these
tests is generally 3 dilutions and 8 mm, respectively. While disk diffusion data are
not subject to evaluation of essential agreement, because zone diameters are not
reported, laboratories should be cognizant that variability also exists for disk testing,
particularly when multiple brands and lots of media and disks are used, as is required
by CLSI when QC ranges are being established.
The reporting of speciﬁc MIC results has the potential to be misinterpreted. The end
user of the data may not be aware of the relative concentrations of the various
antimicrobials in different body compartments, to place the data in a clinical context,
and not all prescribers are aware of the relationship between MIC values and categor-
ical interpretations for a speciﬁc antimicrobial agent (26). Numerical values may result
in confusion, with some health care providers concluding that the best therapy is the one
with the lowest numerical MIC, which frequently does not correlate with the most appro-
priate therapy for a given infection. For example, in the setting of urinary tract infections,
nitrofurantoin may exhibit a much higher numerical MIC value than a -lactam antibiotic,
but nitrofurantoin is highly concentrated in the urine and often is an appropriate selection
for the treatment of uncomplicated urinary tract infections (27, 28).
The predominant value of MIC-based dosing of antimicrobials is for isolates with
MICs that approach the resistance breakpoint or are immediately above it. In general,
such isolates represent a minority of the bacterial population, although there are
instances in which breakpoints are found within the wild-type distribution (e.g., the
cefazolin breakpoint for Enterobacteriaceae). Although it is not routinely used for this
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purpose, disk testing can often provide more data on the relative “resistance” or
“susceptibility” of an isolate than can MICs determined with commercial AST devices
that test a truncated range of antimicrobial concentrations. For instance, an isolate for
which no zone of growth inhibition is observed would be predicted to have a higher
MIC than does an isolate with a zone of growth inhibition approaching the resistance
breakpoint. Similarly, an isolate with a very large zone of growth inhibition would be
predicted to be more susceptible than an isolate with a zone of inhibition at the
susceptibility breakpoint. However, it should be cautioned that disk zones should never
be reported to clinicians, because the correlation of disk zones and MICs may not be as
good for MICs above or below the breakpoint. If the disk zone size suggests an isolate
outside the wild-type distribution and clinicians desire a MIC value, then the MIC can
be determined by reﬂex testing, if available.
Additional beneﬁts of disk diffusion testing include low cost and ease of implemen-
tation. Disk tests can be performed with Mueller-Hinton agar, which is available from
multiple manufacturers, and with little or no additional instrumentation (e.g., calipers or
a ruler and an incubator). CLSI recommendations for veriﬁcation studies to be per-
formed prior to implementation of a new disk test in laboratories that already perform
disk diffusion testing are minimal. Typically, only 5 clinical isolates are required to be
tested in order to verify disk accuracy. Laboratories that are implementing disk diffusion
testing as a new method for the laboratory should test at least 30 isolates (29).
Challenge isolates, with reference BMD MIC data, are available free of charge from the
Centers for Disease Control-FDA organism bank, for laboratories to use to verify the
performance of AST devices for most new antimicrobial agents (https://www.cdc.gov/
drugresistance/resistance-bank/index.html). An additional source of isolates may be the
drug sponsor.
Use of disk diffusion testing for new antimicrobials allows laboratories to customize
the panel of new antimicrobials to be tested, to address local or institutional resistance
issues and to support antimicrobial stewardship endeavors. In contrast, automated
devices are typically available with predeﬁned antimicrobial panels that cannot be
changed. Similarly, in times of antimicrobial shortage, it is relatively easy for a labora-
tory to add an antimicrobial disk to the panel of disks routinely being tested. Both CLSI
and EUCAST are developing direct-from-blood-culture disk diffusion tests, for which
results may be read at earlier time points than the traditional 18 to 20 h (30, 31).
Disadvantages of disk diffusion testing include the absence of a disk method for
anaerobic bacteria and the fact that certain antimicrobials, such as daptomycin and
colistin, cannot be tested with disks.
TOOLS TO AID IN STANDARDIZATION OF DISK DIFFUSION TESTING IN THE
CLINICAL LABORATORY
Accurate performance of disk diffusion testing relies on proﬁcient technologists. The
major contributor to disk diffusion testing variability has been shown to be interoperator
variability, including the methods used to prepare the inoculum and to streak the Mueller-
Hinton agar plate (15). Several tools are now available to facilitate operator standardization,
including both recently developed educational materials and next-generation instrumen-
tation. The EUCAST website (http://www.eucast.org/ast_of_bacteria) includes several
resources that outline the steps for performing and interpreting disk diffusion tests;
these are available in many languages. The CLSI M02 document includes detailed
instructions for performing disk diffusion, and new to the 2018 edition is a disk diffusion
reading guide, with pictures that outline how to evaluate challenging disk zones (32).
Several instruments have been developed to automate the discrete steps of disk
diffusion testing, including photometric devices to standardize inoculum preparation,
automated plate streakers, and digital imaging systems to read disk diffusion zones of
inhibition. In one study, automated streaking signiﬁcantly reduced interoperator dif-
ferences in disk diffusion zones of inhibition (33). Instrumentation that automates
reading of disk diffusion test results includes the FDA-cleared BIOMIC system (Giles
Scientiﬁc, Inc. Santa Barbara, CA), as well as several systems not yet available in the
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United States (34). Such systems allow both objective and automated assessment of
zones of inhibition, with application of expert rules software that laboratories have
come to rely on with automated AST devices. The use of automated readers has been
shown to signiﬁcantly improve the precision of disk diffusion zone assessments (35).
Furthermore, with the use of digital readers, early reading and interpretation of results
for some antimicrobial agents and microorganisms may be possible. One study dem-
onstrated that ME and VME rates were 1% after only 10 h of incubation, compared to
a full 20 h of incubation, for a collection of 88 challenge isolates of Enterobacteriaceae
(36). Finally, fully automated solutions to disk diffusion testing are emerging, including
total laboratory automation systems. These will further simplify the process of disk
diffusion testing by automating colony picking, inoculum preparation, incubation, and
reading (37). The use of these fully automated disk diffusion solutions will expedite
reporting and will ﬁt into today’s laboratory workﬂow.
SUMMARY
Antimicrobial disks are among the ﬁrst AST devices available to clinical laboratories
for new antimicrobial drugs. Testing of such agents is critical to optimize clinical
outcomes, because resistance is not predictable. Disk development and quality are
carefully monitored by both the drug sponsor during development and the manufac-
turer during marketing. Educational resources and new instrumentation are available to
aid laboratories in performing disk diffusion testing. While MIC values can be helpful for
interpreting susceptibility results, MIC methods are not always available for new drugs.
Ultimately, if the option is a disk diffusion test result or no result at all for new
antimicrobials, most clinicians would favor a disk diffusion result.
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